Stay updated on Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    A new revision tag (v3.5.3) appears, replacing v3.5.2 and indicating a page-level update rather than changes to study details.
    Difference
    0.0%
    Check dated 2026-04-27T20:13:46.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    Revision updated from v3.5.0 to v3.5.2. No visible changes to page content or layout.
    Difference
    0.0%
    Check dated 2026-04-20T16:30:39.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    22 days ago
    Change Detected
    Summary
    Padova, PD, Italy, 35128 was added as a study location and later removed. A Lancet Oncology publication reference for MIRASOL (with an Erratum) was added and later removed.
    Difference
    0.0%
    Check dated 2026-04-06T08:45:00.000Z thumbnail image
  5. Check
    36 days ago
    Change Detected
    Summary
    Page revision updated from v3.4.3 to v3.5.0.
    Difference
    0.0%
    Check dated 2026-03-23T01:21:24.000Z thumbnail image
  6. Check
    50 days ago
    Change Detected
    Summary
    Publication citation updated: added Lancet Oncology 2025 paper on MIRASOL patient-reported outcomes with an erratum; the previous v3.4.2 citation was removed.
    Difference
    0.0%
    Check dated 2026-03-08T23:23:05.000Z thumbnail image
  7. Check
    72 days ago
    Change Detected
    Summary
    Added Fallopian tube cancer as a listed condition on the study page and updated the page revision to v3.4.2.
    Difference
    0.0%
    Check dated 2026-02-15T14:26:12.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial page.